For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development expenses | 186,331 | 235,992 | 227,442.75* | |
| General and administrative expenses | 210,311 | 287,922 | 527,816.25* | |
| Total operating expenses | 396,642 | 523,914 | 755,259* | |
| Interest income | 9,206 | 448 | 6,228.75* | |
| Gain on disposal of subsidiaries | 7,346,684 | - | - | |
| Other expense, net | - | - | 65,712* | |
| Other income (expense), net | 42,930 | 136,565 | - | |
| Total other income (expense), net | 7,398,820 | 137,013 | -59,483.25* | |
| Income (loss) before tax expense | 7,002,178 | -386,901 | -814,742.25 | |
| Loss from discontinued operation (net of tax) | -144,257 | - | - | |
| Net income (loss) for the period | 6,857,921 | -386,901 | -814,742.25* | |
| Foreign currency translation gain, net of taxes | - | -86,539 | 54,586.5* | |
| Foreign currency translation (loss) gain, net of taxes | -380,403 | - | - | |
| Total comprehensive income (loss) | 6,477,518 | -473,440 | -760,155.75 | |
| Basic EPS | 0.31 | -0.02 | -0.037 | |
| Diluted EPS | 0.31 | -0.02 | -0.037 | |
| Basic Average Shares | 21,640,000 | 21,640,000 | 20,525,699 | |
| Diluted Average Shares | 21,640,000 | 21,640,000 | 20,525,699 | |
Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc. (ADVB)